Condition
Progeria
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed3
Unknown2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02579044Phase 1Enrolling By InvitationPrimary
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
NCT00916747Phase 2UnknownPrimary
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
NCT03895528UnknownPrimary
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
NCT00094393CompletedPrimary
Clinical Studies of Progeria
NCT00425607Phase 2CompletedPrimary
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
NCT00879034Phase 2CompletedPrimary
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Showing all 6 trials